Palm-Derived Tocotrienols in Polyendocrine Metabolic Ovarian Syndrome (Formerly PCOS): From Insulin Resistance and Adipose Inflammation to a Precision Translational Agenda a Critical Review

Abstract

Polycystic ovary syndrome, recently renamed polyendocrine metabolic ovarian syndrome (PMOS), is increasingly recognised as a heterogeneous multisystem disorder in which insulin resistance, compensatory hyperinsulinaemia, androgen excess, adipose dysfunction, chronic inflammation, oxidative stress and metabolic comorbidity interact with reproductive dysfunction. Palm-derived tocotrienols represent a biologically interesting but clinically untested adjunct in this condition. This critical qualitative review evaluates the translational rationale for investigating tocotrienols in PMOS while explicitly distinguishing biological plausibility from established clinical efficacy. Contemporary evidence was interpreted across PMOS pathophysiology, tocotrienol pharmacology, vitamin E intervention studies and tocotrienol trials in related metabolic disorders. Tocotrienols show potentially relevant effects on insulin resistance, inflammatory and oxidative biomarkers, hepatic steatosis, adipokines and other cardiometabolic variables in non-PMOS populations. However, no robust tocotrienol-specific randomised clinical evidence currently establishes effects on androgen excess, sex-hormone-binding globulin, ovulation, menstrual regularity, fertility or patient-centred outcomes in PMOS. Evidence from alpha-tocopherol cannot be directly transferred because tocopherols and tocotrienols differ structurally and pharmacokinetically. Future research should prioritise standardised palm-derived preparations, pharmacokinetic verification, phenotype-enriched recruitment and integrated metabolic-reproductive endpoints. Tocotrienols should therefore be regarded as a precision translational hypothesis rather than an established PMOS therapy.